Cargando…

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation

Detalles Bibliográficos
Autores principales:	Lorentino, Francesca, Xue, Elisabetta, Mastaglio, Sara, Giglio, Fabio, Clerici, Daniela, Farina, Francesca, Piemontese, Simona, Bruno, Alessandro, Lazzari, Lorenzo, Ruggeri, Annalisa, Guggiari, Elena, Lunghi, Francesca, Assanelli, Andrea A., Marktel, Sarah, Marcatti, Magda, Carrabba, Matteo G., Bernardi, Massimo, Corti, Consuelo, Peccatori, Jacopo, Ciceri, Fabio, Greco, Raffaella, Lupo-Stanghellini, Maria Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131907/ https://www.ncbi.nlm.nih.gov/pubmed/35078219 http://dx.doi.org/10.1182/bloodadvances.2021006213

Ejemplares similares

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
por: Greco, Raffaella, et al.
Publicado: (2019)

Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients
por: Serpenti, Fabio, et al.
Publicado: (2021)

Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2021)

Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation
por: Giglio, Fabio, et al.
Publicado: (2022)

Minnesota acute graft-versus-host disease risk score predicts survival at onset of graft-versus-host disease after post-transplant cyclophosphamide prophylaxis
por: Ardizzoia, Federica, et al.
Publicado: (2022)

Treosulfan-Based Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation: Long-Term Results From a Phase 2 Clinical Trial
por: Lazzari, Lorenzo, et al.
Publicado: (2021)

Addition of a Single Low Dose of Anti T-Lymphocyte Globulin to Post-Transplant Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplant: A Pilot Study
por: Xue, Elisabetta, et al.
Publicado: (2022)

Lung Ultrasound to Evaluate Invasive Fungal Diseases after Allogeneic Hematopoietic Stem Cell Transplantation
por: Raffaella, Greco, et al.
Publicado: (2019)

Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature
por: Farina, Francesca, et al.
Publicado: (2022)

COVID-19 in recipients of allogeneic stem cell transplantation: favorable outcome
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2021)

Following-up allogeneic transplantation recipients during the COVID-19 pandemic
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2020)

Levofloxacin prophylaxis vs no prophylaxis in patients with neutropenia within an endemic country for carbapenem-resistant GNB
por: Clerici, Daniela, et al.
Publicado: (2022)

Nanosphere's Verigene(®) Blood Culture Assay to Detect Multidrug-Resistant Gram-Negative Bacterial Outbreak: A Prospective Study on 79 Hematological Patients in a Country with High Prevalence of Antimicrobial Resistance
por: Greco, Raffaella, et al.
Publicado: (2019)

1559. Hematopoietic Cell Transplantation with Post-transplant Cyclophosphamide: Impact of Donor Type on Pre-engraftment Blood-Stream Infections
por: Oltolini, Chiara, et al.
Publicado: (2018)

MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?
por: Bernardi, Massimo, et al.
Publicado: (2022)

Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia
por: Giglio, Fabio, et al.
Publicado: (2023)

P1549: HIGH PREVALENCE OF RESPIRATORY SYNCYTIAL VIRUS IN HAEMATOLOGICAL PATIENTS AFTER COVID19 WAVES.
por: Farina, Francesca, et al.
Publicado: (2023)

Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors
por: Liberatore, Carmine, et al.
Publicado: (2022)

PB2426: SORAFENIB MAINTENANCE TAILORED TO FLT3-MUTATED AML AFTER ALLOGENEIC HCT IS HIGHLY FEASIBLE AND EFFECTIVE: A REAL-LIFE EXPERIENCE
por: Diral, Elisa, et al.
Publicado: (2023)

PB2575: HIGH INCIDENCE OF RESPIRATORY TRACT INFECTIONS FOLLOWING COVID-19 WAVES IN PATIENTS WITH PLASMA CELL DYSCRASIAS
por: Farina, Francesca, et al.
Publicado: (2023)

GVHD Prophylaxis 2020
por: Gooptu, Mahasweta, et al.
Publicado: (2021)

Improving the safety of cell therapy with the TK-suicide gene
por: Greco, Raffaella, et al.
Publicado: (2015)

Early molecular diagnosis of aspergillosis in a patient with acute myeloid leukaemia
por: Greco, R, et al.
Publicado: (2014)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
por: Ferla, Valeria, et al.
Publicado: (2022)

Impact of tixagevimab/cilgavimab prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplants and CAR T-cell therapy: a single center experience.
por: Xue, Elisabetta, et al.
Publicado: (2023)

Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia
por: Lazzari, Lorenzo, et al.
Publicado: (2022)

Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation
por: Liberatore, Carmine, et al.
Publicado: (2021)

Inflammasome effects in GvHD
por: Koehn, Brent H., et al.
Publicado: (2015)

Targeting Cytokines in GVHD Therapy
por: Kumar, Sandeep, et al.
Publicado: (2017)

Editorial: Interferons and GvHD
por: Kim, Boram, et al.
Publicado: (2022)

Regulatory T Cells in GVHD Therapy
por: Guo, Wen-wen, et al.
Publicado: (2021)

Milestones in acute GVHD pathophysiology
por: Socie, Gerard, et al.
Publicado: (2022)

Utility of eGVHD App for bedside GVHD assessment in a high-volume BMT center
por: Chhabra, Prashant, et al.
Publicado: (2023)

Posttransplant cyclophosphamide vs tacrolimus–based GVHD prophylaxis: lower incidence of relapse and chronic GVHD
por: Maurer, Katie, et al.
Publicado: (2023)

Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes
por: Herzog, Shannon, et al.
Publicado: (2023)

Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD
por: Hildebrandt, G C, et al.
Publicado: (2011)

Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium
por: DeFilipp, Zachariah, et al.
Publicado: (2021)

Human herpesvirus 6–specific T-cell immunity in allogeneic hematopoietic stem cell transplant recipients
por: Noviello, Maddalena, et al.
Publicado: (2023)

Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract
por: Biavasco, Francesca, et al.
Publicado: (2022)

Gut-grabbing T cells trigger GVHD
por: Van Epps, Heather L.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_ds8tlikgv1rir5vprunqohmkce